Æȷοì
Timothy Hughes
Timothy Hughes
SAHMRI, University of Adelaide, SA Pathology
sahmri.comÀÇ À̸ÞÀÏ È®ÀÎµÊ - ȨÆäÀÌÁö
Á¦¸ñ
Àοë
Àοë
¿¬µµ
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien, F Guilhot, RA Larson, I Gathmann, M Baccarani, F Cervantes, ...
New England Journal of Medicine 348 (11), 994-1004, 2003
46182003
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ...
New England Journal of Medicine 355 (23), 2408-2417, 2006
43722006
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...
Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013
25412013
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
G Saglio, DW Kim, S Issaragrisil, P Le Coutre, G Etienne, C Lobo, ...
New England Journal of Medicine 362 (24), 2251-2259, 2010
20782010
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ...
Journal of clinical oncology 27 (35), 6041, 2009
18512009
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ...
Blood 108 (6), 1809-1820, 2006
18202006
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford, Z Rudzki, A Hochhaus, ML Hensley, ...
New England Journal of Medicine 349 (15), 1423-1432, 2003
15952003
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL ¡¦
T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ...
Blood 108 (1), 28-37, 2006
15242006
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ...
New England journal of medicine 371 (11), 1005-1015, 2014
14642014
Long-term outcomes of imatinib treatment for chronic myeloid leukemia
A Hochhaus, RA Larson, F Guilhot, JP Radich, S Branford, TP Hughes, ...
New England Journal of Medicine 376 (10), 917-927, 2017
12272017
A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias
JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ...
New England Journal of Medicine 369 (19), 1783-1796, 2013
12182013
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
CG Mullighan, CB Miller, I Radtke, LA Phillips, J Dalton, J Ma, D White, ...
Nature 453 (7191), 110-114, 2008
11932008
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
A Hochhaus, M Baccarani, RT Silver, C Schiffer, JF Apperley, F Cervantes, ...
Leukemia 34 (4), 966-984, 2020
11902020
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A Hochhaus, SG O'brien, F Guilhot, BJ Druker, S Branford, L Foroni, ...
Leukemia 23 (6), 1054-1061, 2009
11292009
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding ¡¦
S Branford, Z Rudzki, S Walsh, I Parkinson, A Grigg, J Szer, K Taylor, ...
Blood 102 (1), 276-283, 2003
9862003
Dynamics of chronic myeloid leukaemia
F Michor, TP Hughes, Y Iwasa, S Branford, NP Shah, CL Sawyers, ...
Nature 435 (7046), 1267-1270, 2005
9762005
Lin28 promotes transformation and is associated with advanced human malignancies
SR Viswanathan, JT Powers, W Einhorn, Y Hoshida, TL Ng, S Toffanin, ...
Nature genetics 41 (7), 843-848, 2009
9302009
International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed ¡¦
M Deininger, SG O'Brien, F Guilhot, JM Goldman, A Hochhaus, ...
Blood 114 (22), 1126, 2009
9242009
High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute ¡¦
S Branford, Z Rudzki, S Walsh, A Grigg, C Arthur, K Taylor, R Herrmann, ...
Blood, The Journal of the American Society of Hematology 99 (9), 3472-3475, 2002
9042002
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
A Hochhaus, G Saglio, TP Hughes, RA Larson, DW Kim, S Issaragrisil, ...
Leukemia 30 (5), 1044-1054, 2016
8632016
ÇöÀç ½Ã½ºÅÛÀÌ ÀÛµ¿µÇÁö ¾Ê½À´Ï´Ù. ³ªÁß¿¡ ´Ù½Ã ½ÃµµÇØ ÁÖ¼¼¿ä.
ÇмúÀÚ·á 1–20